Shares of Regeneron Pharmaceuticals, Inc. (REGN) declined on Monday morning after the company announced a strategic collaboration with Parabilis Medicines to develop a new class of antibody-based therapies.
The stock is currently trading at $623.12, down $75.14 or 10.76%, on the Nasdaq. It opened at $615.93 after closing the previous session at $698.25. The stock has traded between $476.49 and $821.11 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.